HNGE — Stock Analysis (March 2026)

Date: 2026-03-27 | Position: Long, 7.4% | By: wsm007

Verdict

Three S-curves stacking, 85% gross margins, Rule of 40 = 82, and a 25% FY26 guide that is mathematically impossible unless the business falls off a cliff in H2. It won't. At 5x run-rate P/S with $180M in annual FCF and zero debt, this is the cheapest quality compounder I own. Stock's up 40% since my Feb analysis — still cheap. Thesis intact. Hold 7.4%. Add on Q1 beat.

The Structural Story

Before I touch a single number, the framing matters. HNGE is not a single-product company growing 50% that will decelerate to 20% and stall. It's a platform with three growth curves at different maturities:

1. Core employer digital MSK (mature growth): 2,830 clients, 53% of Fortune 100, 97% retention. Growing 25-30% organically. The beachhead.
2. Engagement-based pricing + yield expansion (growth phase): 50% of lives on EBP, yield 3.4% → 3.9% YoY. NDR >110%. This is the "expand" in land-and-expand — same clients, more revenue per life.
3. Non-ASO channels (embryonic): Medicare Advantage, FEP, fully-insured = 2.6M lives, +130% YoY. New TAM that's uncorrelated with employer ASO saturation.

And two more behind those: 4. HingeSelect (pre-revenue): Hybrid virtual+in-person network. "Not assuming really any revenue" in FY26. CEO: "1 of our most enduring competitive advantages." 2027+ contributor. 5. Robin AI (structural enabler): 47% more members served with flat care team costs. 28% reduction in async session time QoQ. This isn't a product — it's the margin expansion engine that funds everything else.

CEO Perez: "We didn't come this far automating physical therapy to stop at physical therapy." That's a sixth growth vector being telegraphed. This is a management team building a platform, not milking a product.

→ When multiple growth vectors stack at different maturities, the single most common analytical error is modeling the whole company at the blended growth rate of the oldest vector. The 25% FY26 guide reflects this error deliberately — management wants to under-promise.

Revenue Growth — The QoQ Grid

Q4 FY25 context: 10.7% QoQ annualises to ~49%. Compare to Q4 FY24's 16.6% (annualises to 87%) and Q4 FY23's 0.1% (effectively flat). The FY24 Q4 was the monster quarter that makes FY25 Q4's YoY look like deceleration. In reality, QoQ growth has been stable at 10-12% for three consecutive quarters — that's a $680M+ run-rate company growing at ~50% annualised.

Q1 FY26 guide: $172M midpoint → implies ~0.8% QoQ vs Q4's $170.7M. Compare Q1 pattern: 1.5% (FY24) → 5.5% (FY25). Either Q1 FY26 reverses an improving trend (unlikely given record client adds in Q4), or this is the same sandbag pattern we saw with FY25 guidance where they guided $572-574M and delivered $588M.

YoY trajectory — the headline concern:

Yes, YoY is decelerating. From 55% to 45.5% in three quarters. Two quarters of YoY deceleration is normally my sell trigger. But the absolute dollar increments tell a different story:

Stable. The company is adding ~$15-16M per quarter in new revenue. YoY percentages are compressing because the denominator is growing — not because dollar growth is slowing. This is textbook "deceleration at scale." Not the same as demand-driven deceleration.

→ I'm not selling a 45% grower with accelerating dollar adds, expanding margins, and record client adds. The deceleration is mathematical, not fundamental.

Revenue — 12 Quarters

Annual: FY23 $292.7M → FY24 $390.4M (+33%) → FY25 $587.9M (+51%) → FY26E $737M guide (+25%)

Margins — The Real Story

This is the story:

Gross margin: 62% (Q1 FY23) → 85% (Q4 FY25). Twenty-three percentage points in three years. Robin AI is doing this — 47% more members served with flat care team headcount, async session time down 28% QoQ. This isn't a one-time efficiency gain. The AI is compounding quarter-over-quarter. Management: "We are currently planning to keep the size of the care team flat once again in 2026." That's another full year of AI leverage flowing through to GM. Path to 90% GM is visible.

Operating margin: -61% (Q1 FY23) → +28% (Q4 FY25). Nearly 90pp of operating leverage in 12 quarters. Total opex as a % of revenue: 84% (FY24) → 57% (Q4 FY25). They didn't slash costs — revenue grew 51% while opex grew modestly. Operating leverage at scale.

FCF: Lumpy (-69MFY23 → +45M FY24 → +$180M FY25). The FY25 number is real — 31% FCF margin on $588M revenue. Q4 alone was $61.5M (36%). The company hit its IPO target FCF margin model "only 7 months after becoming public." FCF per share: $2.12 on 85M diluted shares.

Rule of 40: 82 (Q4). Revenue growth 45.5% + FCF margin 36.0%. Perez named the peer group: "less than 10 other public tech companies with over $500 million of revenue, over 50% growth and 30% free cash flow margin. It's really just Palantir and Nvidia." He's not wrong.

Leading Indicators — All Green

The yield model is the compounding engine. Revenue = Eligible Lives x Yield. Both legs expanding simultaneously:

• Eligible lives +28% YoY (20.1M, up from 15.7M)
• Yield +50bps YoY (3.9%, up from 3.4%)

First-year cohort yield at 3.3% vs mature portfolio yield at 3.9% → 60bps of built-in expansion as cohorts season. Combined with EBP adoption (now 50% of lives), the yield curve has room to run to 4.5%+ over the next 2-3 years.

Client adds at ATH (+270 in Q4) is the single most bullish leading indicator. New clients take 2-3 quarters to ramp to full engagement. The Q4 cohort won't be at mature yield until Q2-Q3 FY26. This is fuel for the back half of FY26 — precisely when management's sandbagged 25% guide would require deceleration.

→ Every leading indicator is at or near records. Not a single headwind.

Guidance — The Sandbag

The math doesn't work for 25%. If Q2-Q4 grow at even the current 10-11% QoQ pace:

To hit $737M, growth must decelerate to ~5% QoQ for Q2-Q4. None of the leading indicators support this.

Assumptions explicitly conservative (from CFO):

• Yield: "Expected flat" (despite 50bps expansion in FY25)
• ASP: "Expected flat"
• HingeSelect: "Not assuming really any revenue"
• CMS access: "More of a 2027 and beyond contribution"
• Non-ASO: "Not modeled meaningfully"

→ Record initial annual guide that is deliberately sandbagged. My base case: FY26 actual $780-820M (33-40% growth).

Competitive Position

Sword Health / Kaia acquisition (Jan 29, 2026):

The 80% win rate claim was from late-2025 Evercore channel checks. Needs updating post-Sword/Kaia. If this drops below 70% by H1 FY26, competitive risk escalates. But HNGE's multi-layer defence would take Sword 3-5 years to replicate.

→ Sword is the most credible competitor, but HNGE owns the U.S. employer market. International expansion just got harder. U.S. TAM (215M addressable lives, 11% penetrated) provides years of runway.

Scuttlebutt — What The Numbers Don't Show

Customer: Google Play 4.9/5 (26.6K reviews) outstanding. Billing complaint pattern structural and persisting — unexpected insurance charges. No FTC action yet but most credible regulatory risk.

Employee: Glassdoor 3.8/5 flat. Management 2.8/5 on Blind. Pre-IPO layoff resentment lingers. But: no new 2026 layoffs, 65 active roles, 2x engineering throughput in FY25. Cultural concern, not operational.

Insider selling (March 23, 2026): CFO Budge $465K + President Pursley 634K—sameday, sameprice(42.26). No confirmed 10b5-1 plan. Combined $1.1M modest vs holdings. Flagged.

Board upgrade: Tyler Sloat (Cloudflare CFO) added to board.

Valuation

Seasonality note: Q4 is HNGE's seasonally strongest quarter. Run-rate flatters slightly. Reality is between run-rate and TTM. Call it ~5.5x revenue, ~16x FCF, ~21x non-GAAP earnings.

Jamin Ball context: Median 30-40% SaaS grower trades at 10-15x forward revenue. Even at guided 25% growth, HNGE should trade at 8-10x. At estimated 33-40% actual growth, 12-15x justified. Current 5.5x is half the fundamental range.

Rule of 40 framework: Score of 82 historically correlates with 15-20x revenue multiples. HNGE at 5.5x trades at ~30% of implied fair value.

FCF yield: $180M FCF / $3.45B mkt cap = 5.2%. For a 40%+ grower. A 20x FCF multiple implies $3.6-4.9B. Current: $3.45B. FCF alone supports the valuation with zero growth premium.

Buyback floor: $185M remaining authorization. Management buying at $40-46 after a 40% run. They're not worried.

→ At 5x run-rate P/S with Rule of 40 = 82, this is still one of the cheapest high-quality assets in public tech. Could double and still not be expensive.

Prior Beliefs vs Current Beliefs

Key Risks

1. YoY deceleration persists. 55% → 45.5%. If Q1 at/below guide ($172M), deceleration narrative hardens. Two consecutive quarters of actual deceleration = reassess.
2. Sword/Kaia competitive intensification. If Sword IPOs and win rate drops below 70%.
3. Non-ASO economics. Unproven at scale. If stalls, "second growth curve" narrative breaks.
4. Insider selling. CFO + President same day, no disclosed 10b5-1. If pace increases post-Q1.
5. Employee sentiment drag. Management 2.8/5 Blind. R&D retention risk if 2x throughput doesn't hold.
6. Billing complaints. Structural employer-pays model confusion. FTC/AG investigation risk.

What I'm Watching

1. Q1 FY26 actuals (late April). >$178M = add. At/below 172M = investigate.<170M = sell.
2. FY26 guide revision cadence. First raise = strong. No raise through Q2 = concern.
3. Win rate data post-Sword/Kaia. Any movement below 75%.
4. Non-ASO disclosed metrics. Revenue contribution at scale. Q2/Q3 FY26.
5. Insider selling patterns. 10b5-1 disclosures. Acceleration = yellow flag.

Action

Hold 7.4%. No change.

The stock is up 40% since my Feb earnings review and the valuation is still attractive. Every leading indicator is green. The S-curves are stacking. But Q1 FY26 is the catalyst — I'm not adding ahead of it when the only new data point since Feb (insider selling) was mildly negative.

If Q1 beats meaningfully (>$178M): → Add to 10%+. The deceleration narrative collapses and the guide raise cycle begins.

If Q1 in-line ($172-178M): → Hold. Watch Q2 closely.

If Q1 misses (<$170M): → Trim or exit. Miss-and-lower in first full year post-IPO with insider selling = broken trust.

The risk/reward remains asymmetric. This is a $600M-and-growing digital health platform with 85% gross margins, 30%+ FCF margins, zero debt, and <12% TAM penetration, trading at 5x run-rate revenue. The market will catch up. I can be patient.

-wsm (Long HNGE, 7.4%)

Appendix: TAM & Penetration

Distribution is locked down at the top. The expansion path is deeper employer penetration (more lives per client via yield expansion) and new channels (non-ASO, HingeSelect referrals, eventually international). Years of runway.